Can a drug combo shrink liver tumors enough for surgery?
NCT ID NCT02350530
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether adding bevacizumab to a powerful four-drug chemotherapy regimen (FOLFOXIRI) could shrink liver tumors in people with colorectal cancer that had spread only to the liver and could not be removed surgically. The goal was to see if more patients could then have surgery to remove all visible cancer. The trial enrolled 138 adults and compared the combination therapy to chemotherapy alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- FOLFOXIRI (a combination of four chemotherapy drugs: irinotecan, oxaliplatin, leucovorin, and 5-fluorouracil) with or without bevacizumab (a drug that blocks blood vessel growth to tumors)
- What this could lead to
- If successful, this approach could help more people with colorectal cancer that has spread to the liver become eligible for surgery, which may improve long-term survival.
- What could go wrong
- This is a phase 2 study with only 138 participants, so results may not apply to everyone. Adding bevacizumab to strong chemotherapy can increase side effects like low white blood cell counts and high blood pressure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Sixth Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, 510655, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can delivering cancer drug directly to the liver shrink tumors?
- Blood biomarkers could replace invasive biopsies for colorectal cancer monitoring
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a Two-Drug combo outsmart resistant colorectal cancer?
- Can a pill boost the immune system to fight Hard-to-Treat cancers?
- Can a Triple-Drug rechallenge tame colorectal cancer?